AU762493B2 - Induction of apoptic or cytotoxic gene expression by adenoviral mediated gene codelivery - Google Patents

Induction of apoptic or cytotoxic gene expression by adenoviral mediated gene codelivery Download PDF

Info

Publication number
AU762493B2
AU762493B2 AU31837/99A AU3183799A AU762493B2 AU 762493 B2 AU762493 B2 AU 762493B2 AU 31837/99 A AU31837/99 A AU 31837/99A AU 3183799 A AU3183799 A AU 3183799A AU 762493 B2 AU762493 B2 AU 762493B2
Authority
AU
Australia
Prior art keywords
cell
gene
promoter
vector
bcl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU31837/99A
Other languages
English (en)
Other versions
AU3183799A (en
Inventor
Elizabeth M. Bruckheimer
Bingliang Fang
Li Ji
Timothy J. Mcdonnell
Jack A Roth
Mona G. Sarkiss
Stephen G. Swisher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Publication of AU3183799A publication Critical patent/AU3183799A/en
Application granted granted Critical
Publication of AU762493B2 publication Critical patent/AU762493B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU31837/99A 1998-03-11 1999-03-11 Induction of apoptic or cytotoxic gene expression by adenoviral mediated gene codelivery Ceased AU762493B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7754198P 1998-03-11 1998-03-11
US60/077541 1998-03-11
PCT/US1999/005359 WO1999046371A2 (en) 1998-03-11 1999-03-11 Induction of apoptotic or cytotoxic gene expression by adenoviral mediated gene codelivery

Publications (2)

Publication Number Publication Date
AU3183799A AU3183799A (en) 1999-09-27
AU762493B2 true AU762493B2 (en) 2003-06-26

Family

ID=22138678

Family Applications (1)

Application Number Title Priority Date Filing Date
AU31837/99A Ceased AU762493B2 (en) 1998-03-11 1999-03-11 Induction of apoptic or cytotoxic gene expression by adenoviral mediated gene codelivery

Country Status (4)

Country Link
EP (1) EP1070122A4 (de)
AU (1) AU762493B2 (de)
CA (1) CA2322663A1 (de)
WO (1) WO1999046371A2 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2404235C (en) * 2000-03-24 2010-09-21 Cell Genesys, Inc. Cell-specific adenovirus vectors comprising an internal ribosome entry site
EP1287153B1 (de) 2000-05-31 2009-09-30 Human Gene Therapy Research Institute Methode und zusammensetzungen für effizienten gentransfer durch transcomplementierende vektoren
US20040091453A1 (en) * 2000-06-02 2004-05-13 Hiroshi Okamoto Pancreatic langerhans beta cell proliferation promoter and apoptosis inhibitor, and screening of candidate compounds for the e drugs
US6579522B1 (en) 2000-06-27 2003-06-17 Genvec, Inc. Replication deficient adenoviral TNF vector
EP1207205A1 (de) * 2000-11-20 2002-05-22 Crucell Holland B.V. Adenovirale Replikone
US20030086903A1 (en) 2001-11-02 2003-05-08 Genvec, Inc. Therapeutic regimen for treating cancer
CA2471719A1 (en) * 2001-12-31 2003-07-17 Dana-Farber Cancer Institute, Inc. Method of treating apoptosis and compositions thereof
JP4511108B2 (ja) 2002-05-31 2010-07-28 オンコリクス インコーポレイテッド ヒトプロラクチン拮抗剤−血管新生阻害剤融合蛋白質
CN100361710C (zh) 2004-06-07 2008-01-16 成都康弘生物科技有限公司 肿瘤细胞专一表达免疫调节因子gm-csf的溶瘤性腺病毒重组体的构建及其应用
US20080081354A1 (en) * 2006-10-02 2008-04-03 Cardiac Pacemakers, Inc. Devices, vectors and methods for inducible ischemia cardioprotection
EP3541803B1 (de) 2016-11-16 2020-12-23 Amgen Inc. Triazolpyridylverbindungen als agonisten des apj-rezeptors
EP3704122B1 (de) 2017-11-03 2021-09-01 Amgen Inc. Fusionierte triazolagonisten des apj-rezeptors
WO2019213006A1 (en) 2018-05-01 2019-11-07 Amgen Inc. Substituted pyrimidinones as agonists of the apj receptor
CN110174456B (zh) * 2019-06-11 2021-09-21 华润双鹤药业股份有限公司 一种测定肺表面活性物质蛋白的方法及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996025507A2 (en) * 1995-02-17 1996-08-22 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Methods of preparation and use of recombinant adenoviral vectors
DE19615803A1 (de) * 1996-04-20 1997-10-23 Boehringer Ingelheim Int CELO-Virus
AU5817299A (en) * 1998-09-10 2000-04-03 Uab Research Foundation, The Adenoviral vector encoding pro-apoptotic bax gene and uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BIOCHEM. BIOPHYS. RES. COMMUN. 1998, 243(2) P 609-16 *
GENOMICS, 1995,26(3), P 592-594 *
J.BIOL.CHEM 1997, 272(27), P 16955-61 *

Also Published As

Publication number Publication date
CA2322663A1 (en) 1999-09-16
AU3183799A (en) 1999-09-27
WO1999046371A3 (en) 2000-08-24
EP1070122A4 (de) 2004-11-10
EP1070122A2 (de) 2001-01-24
WO1999046371A9 (en) 2000-02-17
WO1999046371A2 (en) 1999-09-16

Similar Documents

Publication Publication Date Title
US6899870B1 (en) Induction of apoptic or cytotoxic gene expression by adenoviral mediated gene codelivery
ES2338288T3 (es) Metodo mejorado para la produccion y purificacion de vectores adenovirales.
AU742898B2 (en) Fas ligand compositions for treatment of proliferative disorders
US7033750B2 (en) Recombinant P53 adenovirus methods and compositions
AU762493B2 (en) Induction of apoptic or cytotoxic gene expression by adenoviral mediated gene codelivery
AU762615B2 (en) Combination of radiotherapy and anti-angiogenic factors
US6251871B1 (en) P16 expression constructs and their application in cancer therapy
AU767880B2 (en) Multigene vectors
Gómez-Navarro et al. Gene therapy for carcinoma of the breast: Pro-apoptotic gene therapy
JP2005500247A (ja) ヒトｍｄａ−７に関わる処置方法
US6517828B1 (en) C-CAM as an angiogenesis inhibitor
US20060193832A1 (en) Use of the sodium iodine symporter to effect uptake of iodine
JP4117367B2 (ja) 腫瘍にあるサイクリンｇ１の発現を阻害する薬剤、その発現伝達体、およびベクター
JP2006519614A (ja) 悪性かつ形質転換した哺乳動物細胞を選択的に殺すペプチド
US7625716B2 (en) Methods for assessing p19-Arf interactions in cMyc
US6737052B1 (en) Induction of programmed cell death by N5 gene
US20010036929A1 (en) Xrcc3 is required for assembly of Rad51-complexes in vivo
US20020169126A1 (en) Compositions and methods for inactivating the Akt oncogene and/or activating the p38 pro-apoptotic gene
US20030138412A1 (en) Inhibition of tumor growth and metastasis by N5 gene
EP1208114A2 (de) Induktion der programmierten zelltod durch das n5 gene
Lagace Genomic Organization of the X-linked Inhibitor of Apoptosis and Identification of a Novel Testis-specific Homologue

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)